COVID-19 has made it ‘financially impossible’ to be open – Top of The Baths
While announcing a temporary closure, Top of The Baths, a well-known hospitality establishment, announced that the pandemic had made it ‘financially impossible’ to operate.
“The negative result has manifested itself in a manner which makes it financially impossible for us to continue to be open at this time. Therefore, we are giving notice that Top of The Baths Restaurant and coffee bar will be temporarily closed until such time as the economical conditions return to a point where the business can meet its daily obligations,” a post on the company’s Facebook page some 20 hours ago said.
The company said it was with “a very heavy heart and tremendous concern for each and everyone” that the decision was made.
“A decision which comes out of the factual reality of COVID-19, resulting in a negative market for our tourism industry. We truly hope that this period of business interruption will be short-lived,” the company added.
According to online research, the company was opened in 1994 by Charlene and Norman Henderson.
Quito's Inn closes
In the meantime, Quito's Ltd, recently announced that it was closing as of January 31, 2021, for the rest of the tourist season because of the effects being felt from the COVID-19 pandemic.
However, it announced later that on second thought, the restaurant, Quito’s Gazebo in Cane Garden Bay would remain open, while the multimillion-dollar hotel, Quito's Inn, would remain closed.
The travel restrictions due to the global pandemic have been hardest on the hospitality sector and those that rely on it for their livelihood.
.jpg)
Follow Us On
15 Responses to “COVID-19 has made it ‘financially impossible’ to be open – Top of The Baths ”
Britain itself is relying on the Oxford vaccine less heavily than India. It approved Pfizer first, and now appears to be rolling that one out faster than the Oxford vaccine, which is widely regarded across Britain as a poor and less preferable cousin to the rest. The Oxford team is now holding out new promises looking ahead but six major problems have been flagged around the Oxford vaccine.
1. Other vaccines are reporting about 90 percent success while the Oxford trial showed 62 percent success. This effectively means a two in five chance you can get the vaccine and still get the virus, though studies show the infection would be less acute.
2. The Oxford trial claimed 90 percent success through a part of the trial where a smaller dosage was given by mistake. Just what was Oxford doing making a mistake like that, in a trial such as this, remains unclear. After all, few trials have mattered more.
3. That 90 percent claim came from a better result with no more than three individuals. Oxford averaged the results out to claim 70 percent success. Those claims of 90 percent and of 70 percent were both rejected by the MHRA, the Medicines and Healthcare Regulatory Authority whose task it is to approve vaccines in Britain.
4. And now a huge ethical issue has come up – it turns out that Oxford did not tell its volunteers through the trial that it made a mistake in giving them an incorrect dosage. It suggested in a note that this may have been a part of the plan, in blurry language intended clearly to cover up its mistakes rather than admit them openly.
5. Not least, Oxford never tested the most vulnerable. Its trials were conducted almost entirely in the 18-55 group, in which the overwhelming majority recover naturally. And so now France and Germany are refusing to use this vaccine on anyone above 65 on the grounds that it has never been tested among the elderly – who need it most.
6. To add to all of this, now results show it offers only limited protection against the South Africa variant of the virus.
This week, the under-pressure Oxford team held out two new promises. One, while offering some protection and lessening the severity of an infection, it also reduces transmissibility, by about two-thirds. That difference is important; a vaccinated person may be protected, but still may infect others; vaccines can protect the lungs but the virus can persist in the upper respiratory tract. Second, it plans to develop an updated vaccine to protect against emerging new variants of the virus. It hopes to have this in place later this year.
I am starting to believe this government is deliberately forcing enterprises out of business so that the cronies can take them over.